These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31523892)

  • 1. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J;
    Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
    Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure.
    Voors AA; Düngen HD; Senni M; Nodari S; Agostoni P; Ponikowski P; Bax JJ; Butler J; Kim RJ; Dorhout B; Dinh W; Gheorghiade M
    J Clin Pharmacol; 2017 Apr; 57(4):440-451. PubMed ID: 27624622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
    Shah SJ; Voors AA; McMurray JJV; Kitzman DW; Viethen T; Bomfim Wirtz A; Huang E; Pap AF; Solomon SD
    JAMA; 2019 Jun; 321(21):2101-2112. PubMed ID: 31162568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
    Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A
    Meibom D; Albrecht-Küpper B; Diedrichs N; Hübsch W; Kast R; Krämer T; Krenz U; Lerchen HG; Mittendorf J; Nell PG; Süssmeier F; Vakalopoulos A; Zimmermann K
    ChemMedChem; 2017 May; 12(10):728-737. PubMed ID: 28488817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Partial AdeNosine A1 receptor agonist in patients with Chronic Heart failure and preserved Ejection fraction (PANACHE) trial.
    Bertero E; Maack C
    Cardiovasc Res; 2019 Jul; 115(8):e71-e73. PubMed ID: 31180465
    [No Abstract]   [Full Text] [Related]  

  • 8. Partial Adenosine A1 Agonist in Heart Failure.
    Dinh W; Albrecht-Küpper B; Gheorghiade M; Voors AA; van der Laan M; Sabbah HN
    Handb Exp Pharmacol; 2017; 243():177-203. PubMed ID: 27770217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
    Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
    Mortensen AL; Rosenfeldt F; Filipiak KJ
    Cardiol J; 2019; 26(2):147-156. PubMed ID: 30835327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
    Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
    JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.